Patients with Langerhans cell histiocytosis (LCH) harbor BRAF V600E and activating mutations of MAP2K1/MEK1 in 50% and 25% of cases, respectively. We evaluated a patient with treatmentrefractory LCH for mutations in the RAS-RAF-MEK-ERK pathway and identified a novel mutation in the MAP2K1 gene resulting in a p.L98_K104 > Q deletion and predicted to be auto-activating.
INTRODUCTION
Langerhans cell histiocytosis (LCH) is a rare disorder characterized by the clonal expansion of Langerhans cells and is associated with a wide range of clinical symptoms. 1 Genomic analysis of patients with LCH have identified several functionally relevant mutations, 2 including BRAF V600E, which are present in over 50% of LCH patients, 3, 4 MAP2K1 (MEK1) mutations, which occur in about 25% of patients, [5] [6] [7] as well as mutations in ARAF, 8 and MAP3K1. 7 The identification of the BRAF V600E mutation in LCH has led to the application of targeted therapy, 9 in particular the use of vemurafenib. 10 MAP2K1 mutations of LCH patients are activating mutations and mutually exclusive of the BRAF V600E mutation. 6 Mutations of genes in the RAS-RAF-MEK-ERK pathway in LCH suggest that targeted therapy with MEK inhibitors may benefit LCH patients. Studies of targeted therapy for MAP2K1 using trametinib have been done for several cancer types 11, 12 including histiocytosis. 13, 14 Here, we describe a patient with LCH harboring a novel mutation in MAP2K1, who underwent treatment with Abbreviations: ARAF, proto-oncogene belonging to RAF family; BRAF, proto-oncogene belonging to RAF family; BRAF V600E, BRAF harboring an activating mutation at amino acid 600; ERK, signaling kinases ERK1 (MAPK3) and ERK2 (MAPK1); LCH, Langerhans cell histiocytosis; MAP2K1, gene encoding MEK1; MAP3K1, gene encoding MEK kinase (MEKK); MEK1, mitogen-activated protein kinase kinase; encoded by the MAP2K1 gene; MEK-MUT, mutated MEK1 harboring the MAP2K1 p.L98_K104 > Q mutation; MEK-WT, wild-type MEK1; PET-CT, positron emission tomography/computed tomography; RAF, kinases involved in signaling including ARAF, BRAF, and c-RAF; RAS, small GTPases involved in signaling including HRAS, KRAS, and NRAS trametinib resulting in disease progression, and subsequent functional analysis of the novel MAP2K1 mutation.
MATERIALS AND METHODS

Mutation analysis
A sample of lymph node from a patient diagnosed with LCH was sent to Foundation Medicine (Cambridge, MA) for FoundationOne R sequencing analysis of a 315-gene panel.
Cloning
The wild-type (MEK-WT) MEK1-GFP plasmid, 15 
Western blot/AlphaLISA
Cellular lysates from transfected cells were normalized for equal loading on gels and AlphaLISA (PerkinElmer; Waltham, MA) kit. Gels were transferred to PVDF membrane (Bio-Rad, Hercules, CA) and probed with antibodies against MEK/p-MEK; ERK/p-ERK; AKT/p-AKT; or COX IV (Cell Signaling Technology, Danvers, MA). Blots were developed using ECL (Thermo Fisher) and imaged. AlphaLISA assay for p-ERK (PerkinElmer) was analyzed as per manufacturer's instruction.
CASE DESCRIPTION
A 16-year-old male was diagnosed with multifocal LCH primarily involving lymph nodes. The patient was treated with LCH-III therapy 16 and initially responded to treatment. One year later, the patient presented with painful right-sided neck swelling and a biopsy of the lesion confirmed recurrence of LCH. The patient was then treated with the oral pan-AKT inhibitor afuresertib as part of a clinical trial. 17 The patient responded to afuresertib therapy and completed a total of 30 weeks of treatment ( Figure 1A) . Several months later, the patient relapsed and was treated with cytarabine 150 mg/m 2 /day for a 5-day course. After two courses, the patient did not show a good response, and vincristine and steroids were added to the therapy. Afterward, the patient received two cycles of clofarabine, after which he was lost to follow-up. Three years after his initial diagnosis, the patient presented again with LCH symptoms and had cancer-related gene mutation analysis performed at Foundation Medicine. The genomic analysis identified a novel mutation in MAP2K1 (MEK1): an 18 bp deletion c293_310del in exon 3 resulting in a p.L98_K104 > Q inframe deletion ( Figure 1B) . Based upon the gene target, the patient received the MEK inhibitor, trametinib, 2 mg once daily. PET-CT whole body evaluation after 8 weeks of treatment showed progressive disease ( Figure 1C ). Treatment with trametinib was discontinued, and the patient was further treated with a combination of clofarabine and cytarabine for three cycles for disease control. Thereafter, the patient's disease was in control to obtain a haploidentical transplant, and more than a year after transplant the patient was doing well. 
RESULTS AND DISCUSSION
In order to evaluate the function of the novel MAP2K1 mutation, we duplicated the p.L98_K104 > Q mutation using an expression construct for GFP-MEK. 15 The p.L98_K104 > Q mutation in MAP2K1 has not been previously described but it is found in a region of the MAP2K1 gene where several other activating mutations have been found 5, 6, 18, 19 ( Figure 1D) . In vitro functional studies show that the MEK inhibitor U0126 can inhibit ERK activation resulting from these mutations in this region of MAP2K1. 6 Another study showed that the p.F53_Q58 > L, p.Q58_E62del, and p.C121S/G128V mutations in MAP2K1 constituently activated ERK and were susceptible in vitro to MEK inhibitors including trametinib. 20 Interestingly, a recent report describes the complete remission of an LCH patient with an MAP2K1 p.E102-I103del mutation treated with trametinib. 14 The described MAP2K1 p.E102-I103del deletion involves six bases that fall inside the p.L98_K104 > Q deletion and has been shown to be an activating mutation. 5, 6 The difference in the response of these two patients, having similar but not identical MAP2K1 mutations, to trametinib could be due to several factors including the structural change in MAP2K1 protein that the larger p.L98_K104 > Q deletion would have on MAP2K1 activity or trametinib binding. The expression of the MAP2K1 p.L98_K104 > Q mutation identified in this LCH patient leads to hyper-activated p-MAP2K1 and increases activation of p-ERK. As seen in these studies, and consistent with the clinical results, this activating MAP2K1 mutation is not responsive to inhibition with MEK inhibitors, including trametinib. Further functional investigation of these MAP2K1 mutations is needed.
Furthermore, it would be of interest to understand the role that the previous therapeutic treatment with afuresertib may have played in the development of this particular resistance-associated mutation.
These results emphasize the importance of the functional assessment of genomic data in assigning treatment for patients with LCH or other cancers, as well as provide evidence for choice of inhibitor in patients with this or similar mutations.
